Name:
mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-en-3-one)
Type:
Androgenic steroid
AKA:
Cheque, Matenon
mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-en-3-one) image
Synthetic substance, no natural derivative
IUPAC Logo
mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-en-3-one) image
Mibolerone, a synthetic anabolic steroid, was developed in the 1960s and is known for its potent anabolic and androgenic effects. It was used in veterinary medicine to promote growth in livestock and has been studied for its potential in treating hormone-related conditions. Mibolerone's use in sports and bodybuilding has raised concerns about abuse and health risks.
Synthetic Substances Image
Mibolerone, an anabolic steroid, enhances muscle growth and performance. As an upper, it improves strength and physical performance. Short-term effects include increased muscle mass, while long-term use can lead to cardiovascular issues and hormonal imbalances. Overdose risks involve severe health complications. Safe use involves medical supervision. Recent research emphasizes its effectiveness and potential for serious side effects.
N/A
Mibolerone, an anabolic steroid, impacts mood and aggression through androgen receptors. Immediate effects include mood enhancement and increased aggression, with long-term use leading to psychological issues and cognitive impairments. Research focuses on its effects on mental health and hormonal balance.
N/A
Mibolerone, an anabolic steroid, has been used in veterinary medicine to prevent estrus in female dogs and in bodybuilding for its muscle-building effects. Anabolic steroids have a long history of use and controversy, from ancient Greek athletes consuming animal testicles for strength to modern doping scandals in sports. The cultural impact of steroids like mibolerone is significant in discussions about fair play, athlete health, and body image. Steroid use has been both glamorized and demonized in media, with high-profile cases highlighting the physical and ethical consequences of performance enhancement.
N/A